Request for Free Sample

CircRNA Synthesis Market Report Scope & Overview:

CircRNA synthesis market size was valued at USD 183.58 million in 2024 and is expected to reach USD 592.84 million by 2032, growing at a CAGR of 15.85% over the forecast period of 2025-2032.

The CircRNA synthesis market is growing rapidly due to the rising interest in circular RNAs for gene regulation, biomarker discovery, and therapeutic applications. Recent advances in RNA sequencing technologies and synthetic biology enable the efficient synthesis and functional characterization of circRNAs. Market demand is furthering growth due to growing investments in RNA-based drug development and expansion of research in oncology, neurology, and rare diseases. Both academic and commercial uptake of circRNA technologies are fully expected to drive this market into accelerated growth.

The U.S. CircRNA synthesis market size was valued at USD 62.32 million in 2024 and is expected to reach USD 198.32 million by 2032, growing at a CAGR of 15.63% over the forecast period of 2025-2032.

North America generates the maximum revenue in the CircRNA Synthesis market, led by the U.S, which has an advanced biotechnological sector, excellent infrastructure to perform RNA experiments, and the highest funding for research and development. Numerous well-established academic institutes and cutting-edge biotech companies complement the platform, reinforcing the region's leadership in the development and synthesis of circRNA.

Market Dynamics:

Drivers

  • Advancements in RNA Technologies are Driving the Market Growth

Development of stable and functional RNA towards various RNA technologies has also facilitated the floor of circular RNA (circRNA) synthesis. Compared with traditional linear RNA, the extreme stability and outstanding resistance to exonuclease degradation of circRNAs have made them excellent delivery vehicles for gene therapy, vaccine delivery, and protein replacement strategies. The resulting technological improvements have facilitated increased specificity in circRNAs synthesis and their editing, along with the large-scale production, which are driving the uptake in pharmaceutical and academic settings.

  • Increasing Attention Towards RNA-Based Therapeutics is Propelling the Market Growth

CircRNAs have emerged as the next big target for RNA-based drug discovery for biopharma. Their special feature of acting as protein templates and regulating gene expression has put circRNAs high on the list of targets for drug targeting. circRNAs can overcome the limitation of linear mRNA therapies, despite their potential to provide immunogenicity or short half-life, they can also be engineered to enlarge the payload and expand application scope. This unprecedented increase in the number of research studies and preclinical trials of circRNA-based therapeutics is driving demand for fast-acting and large-scale synthesis platforms, contributing to the growth in the market.  

Restraint

  • Absence of Standardized Protocols and Analytical Methods is Restraining the Market from Growing

The lack of standard procedures for the synthesis, purification, enrichment, quantification, and quality assessment of circRNAs represents a critical bottleneck in the field. Compared to linear RNA, circRNA consists of a covalently closed loop structure, which presents challenges for detection and validation with traditional approaches. Public laboratories currently employ various approaches (e.g., RNase R treatment, divergent primers in qPCR, or dedicated RNA-seq pipelines), contributing to non-uniform results and a lack of reproducibility between studies.

The unavailability of such standardization not only limits the potential of academic research but also negatively impacts the scalability and regulatory approval of these novel circRNA-based diagnostics and therapeutics. Lack of defined guidelines leads to obstacles for ensuring quality, consistency, and safety of products, and limits the willingness of pharmaceutical or biotech companies to commit major funds to commercial applications. As a result, this continues to be one of the major constraints in which the market is experiencing a maturity lag and limited uptake.

Segmentation Analysis:

By Product & Service

The reagents & kits segment dominated the CircRNA synthesis market share with a 48.25% in 2024, as these products are essential for achieving consistently accurate, high-throughput, and reproducible synthesis processes, both in a research and clinical setting. They are used in a wide range of molecular biology labs due to their convenience, reproducibility, quality, and compatibility with high-throughput platforms. In addition, a strong interest in academic and commercial research on circRNA functions, therapeutic applications, and biomarker development has generated increased demand for high-quality kits and reagents to support experimental workflows.

The services segment is expected to grow at the fastest rate during the forecast period, owing to the increasing complexity of circRNA-based research and demand for personalized synthesis, sequencing, and bioinformatics analysis. To alleviate operational burden and quicken discovery timelines, many research institutions and biotech companies are now outsourcing these services to specialized providers. Similarly, demand for end-to-end service offerings that involve the synthesis and functional validation of circRNA is likely to witness increased uptake owing to the increasing number of circRNA therapeutics likely to enter downstream stages of product development over the next few years, a factor anticipated to accelerate the growth of this segment.

 By Type of Synthesis

The enzymatic synthesis segment accounted for the largest share of the circRNA synthesis market in 2024 and is expected to grow during the forecast period due to high efficiency, scalability & the ability to produce circRNA with minimal contamination. Enzymatic methods, including ligation and permuted intron-exon (PIE) strategies, provide greater precision in circularizing RNA without the use of extreme conditions or hazardous reagents, both of which are key in maintaining RNA integrity. During research and the initial stage of therapy development, high yields of biologically active circRNAs are crucial, and these methods have been broadly utilized.

The chemical synthesis segment is expected to grow at a significant rate over the forecast period due to improvements made in synthetic chemistry, automation, and precision engineering. While the in vivo transfection of circRNA provides limited customization of circRNA sequences with lesions, which is more suitable for basic research, chemical synthesis has more flexibility on the customization of circRNA sequences and the introduction of chemical modifications, which is regarded as a high-throughput technology and a new concept in therapeutics. Recently, circRNA-based therapeutics (i.e., gene therapy and cancer immunotherapy) are burgeoning, highlighting the urgent need for chemically synthesized circRNAs with high stability and reagent-specific functions.

By Application

The therapeutics development segment dominated the circRNA synthesis market in 2024 it is due to the rising interest in circular RNAs as both precision medicine and RNA-based therapeutics tools. Due to their remarkable stability, low immunogenicity, and high translational efficiency, circRNAs are attractive candidates for therapeutic applications, especially in oncology, cardiovascular disease, and neurological disorders. The increased focus on clinical studies and collaborative efforts between these pharmaceutical companies and traditional academic institutions has drawn a list of several circRNA-based therapeutic candidates in the pipeline, along with some new investments in synthesis platforms more closely designed for therapeutic use.

The drug discovery segment is expected to grow at the highest rate over the forecast period as more circRNAs are being utilized in preclinical and target validation steps of drug discovery. They are relatively stable, and circRNAs are being widely investigated as potential biomarkers and molecular tools for understanding regulatory networks and disease. They are characterized by a distinctive circular structure and wide-ranging regulatory roles that support their potential as novel therapeutic target identifiers.

By End Use

In 2024, the pharmaceutical and biotechnology companies segment held the largest share of the circRNA synthesis market due to major investments by pharmaceutical and biotechnology companies in advancements in RNA-based therapeutic platforms. They are well-positioned, both with a strong R&D infrastructure and funding ability to translate circRNA research into the development of clinical therapeutics. In this segment, the growing attention towards RNA-targeted drug discovery, demand for new therapeutic modalities, and collaborations with RNA technology startups have continued to drive circRNA synthesis solutions.

In the forecast period, the academic and research institutes segment is projected to grow at the fastest rate due to the rising interest in the biological functions and regulatory mechanisms of circRNAs, particularly their involvement in the regulation of gene expression, disease development and progression, and cellular signaling, which is likely contributing to the increased output. Academic institutions are quickly implementing circRNA synthesis technologies as government agencies and private foundations increase funding for RNA biology research.

Regional Analysis:

North America dominated the CircRNA synthesis market trend with a 44.6% market share in 2024, owing to the highly developed biotechnology and pharmaceutical industry, and with the presence of a large amount of funding, both government and private sector support. The high presence of market players, academic research institutes, and infrastructure on RNA-based therapeutics around the region delivers aptitude for backing RNA diagnostics development in the region. The increasing adoption of next-generation sequencing and transcriptomics technologies, as well as the increasing number of clinical trials, are further driving the demand for circRNA synthesis in the region.

The CircRNA synthesis market growth in Asia Pacific is due to the increasing biotechnology government initiatives, rising investments in genomic research, and growing collaborations with global pharmaceutical companies. With biotech startups fostered by growing government support and more friendly regulations, nations like China, Japan, and South Korea quickly build up their RNA game. Moreover, the increasing prevalence of chronic diseases and the growing need for personalized medicine are also significantly promoting the fast growth rate of this region.

Europe is expected to emerge as a significant regional circRNA synthesis market analysis due to well-established pharmaceutical and biotechnology infrastructure, with the government providing solid support for genomics studies, and increasing academic and commercial research partnerships. Germany, the UK, and France have well-established clinical research organizations and a strong tax, research, and development base, coupled with access to skilled R&D centres that are leveraging RNA-based drug discovery initiatives.

In addition, increasing investments in personalized medicine and molecular diagnostics are expected to result in an upsurge in the demand for highly advanced RNA synthesis technology within the region. European regulators are also gradually giving the nod to RNA-based drugs, so the climate of innovation is good! This synthetic and institutional, and policy-driven momentum paves the way for Europe to be a significant player in the gene-drives and circRNAs synthesis market globally.

Growth in the circRNA synthesis market in Latin America and the MEA regions is moderate in over the forecast period, due to the awareness about the role and benefits of RNA-Based Technologies, coupled with the expanding academic and clinical research activities although currently trailing in large-scale biotechnology infrastructure, there are gradual market developments fuelled by a better healthcare systems, investments in life sciences and partnerships with global research institutions taking place in these regions. In addition, increasing government initiatives to improve biomedical research and the rising interest in precision medicine are also providing significance for the continued growth of the circRNA synthesis technologies.

Key Players:

CircRNA synthesis market companies are Synbio Technologies, GenScript, Creative Biogene, OriGene Technologies, Thermo Fisher Scientific, Bio-Synthesis Inc., Twist Bioscience, Syntezza Bioscience, VectorBuilder, Vigene Biosciences, Dharmacon (Horizon Discovery), Eurofins Genomics, Bioneer Corporation, Sangon Biotech, TriLink BioTechnologies, Baseclick GmbH, Integrated DNA Technologies (IDT), Macrogen, GeneUniversal, Genewiz, and other players.

Recent Developments:

  • September 18, 2023 – GenScript Biotech Corporation, a global leader in life science research tools and services, today announced the expansion of its in vitro transcription (IVT) mRNA synthesis platform. GenScript has added new tailored services for circular RNA (circRNA) synthesis and lipid nanoparticle (LNP) formulation to help facilitate cutting-edge research and therapy development efforts.

  • August 2024 – Abogen Biosciences has developed a very effective RNA circularization platform called the Cis-Splicing System (Cis-System). The new system enables the creation of circular RNA (circRNA), marking a milestone in RNA-based therapeutic technologies.

    CircRNA Synthesis Market
    Report Attributes Details
    Market Size in 2024 USD 183.58 million 
    Market Size by 2032 USD 592.84 million 
    CAGR CAGR of 15.85% From 2025 to 2032
    Base Year 2024
    Forecast Period 2025-2032
    Historical Data 2021-2023
    Report Scope & Coverage Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
    Key Segments • By Product & Service (Reagents & Kits, Instruments, Services)
    • By Type of Synthesis (Chemical Synthesis, Enzymatic Synthesis, In vitro Transcription-Based Synthesis)
    • By Application (Therapeutics Development, Drug Discovery, Gene Therapy, RNA Vaccine Development, Functional Genomics Studies, Molecular Diagnostics)
    • By End Use (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Contract Research Organizations (CROs), Diagnostic Laboratories)
    Regional Analysis/Coverage North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
    Company Profiles CircRNA synthesis market companies are Synbio Technologies, GenScript, Creative Biogene, OriGene Technologies, Thermo Fisher Scientific, Bio-Synthesis Inc., Twist Bioscience, Syntezza Bioscience, VectorBuilder, Vigene Biosciences, Dharmacon (Horizon Discovery), Eurofins Genomics, Bioneer Corporation, Sangon Biotech, TriLink BioTechnologies, Baseclick GmbH, Integrated DNA Technologies (IDT), Macrogen, GeneUniversal, Genewiz, and other players.